Sign in or create an account to add this stock to your watchlist.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts. This segment also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. The Group and Specialty segment provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups. It also offers military services, such as TRICARE South Region contract. The Healthcare Services segment provides pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. The Individual Commercial segment offers individual commercial fully-insured medical health insurance benefits under the HumanaOne brand. The company also provides closed-block long-term care insurance policies. As of December 31, 2017, it had approximately 14 million members in medical benefit plans, as well as approximately 7 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Industry, Sector and Symbol
Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
SymbolNYSE:HUM
CUSIP44485910
Phone502-580-1000
Debt
Debt-to-Equity Ratio0.47
Current Ratio1.55
Quick Ratio1.55
Price-To-Earnings
Trailing P/E Ratio25.15
Forward P/E Ratio21.09
P/E Growth1.51
Sales & Book Value
Annual Sales$53.77 billion
Price / Sales0.76
Cash Flow$15.4932 per share
Price / Cash19.04
Book Value$73.22 per share
Price / Book4.03
Profitability
EPS (Most Recent Fiscal Year)$11.71
Net Income$2.45 billion
Net Margins3.36%
Return on Equity16.74%
Return on Assets5.60%
Miscellaneous
Employees45,900
Outstanding Shares137,680,000
Humana (NYSE:HUM) Frequently Asked Questions
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana announced a quarterly dividend on Thursday, April 19th. Shareholders of record on Friday, June 29th will be given a dividend of $0.50 per share on Friday, July 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend is Thursday, June 28th. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana declared that its Board of Directors has authorized a stock buyback program on Friday, December 15th 2017, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.
How were Humana's earnings last quarter?
Humana (NYSE:HUM) posted its earnings results on Wednesday, May, 2nd. The insurance provider reported $3.36 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.21 by $0.15. The insurance provider had revenue of $14.28 billion for the quarter, compared to the consensus estimate of $14.22 billion. Humana had a net margin of 3.36% and a return on equity of 16.74%. During the same quarter last year, the company earned $2.75 earnings per share. View Humana's Earnings History.
When is Humana's next earnings date?
What guidance has Humana issued on next quarter's earnings?
Humana updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $13.70-14.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.87.
What price target have analysts set for HUM?
17 Wall Street analysts have issued 12 month price objectives for Humana's shares. Their forecasts range from $221.00 to $330.00. On average, they anticipate Humana's stock price to reach $277.2941 in the next year. View Analyst Ratings for Humana.
What are Wall Street analysts saying about Humana stock?
Here are some recent quotes from research analysts about Humana stock:
- 1. According to Zacks Investment Research, "Shares of Humana have outperformed the industry year to date. The insurer is well-poised for growth on its strong government business. Its top line has been witnessing an uptrend for the past several years. Sufficient generation of cash flow has helped the company take up many capital deployment initiatives aimed at enhancing its shareholders’ value. Humana’s sound balance sheet and a disciplined capital management remain major tailwinds. Following better-than-expected first-quarter results, the company provided a strong guidance for 2018. Also, the company has exited the individual commercial business effective Jan 1, 2018. Rising level of expenses persistently weighs on the bottom line. With respect to quarterly results, Humana’s first-quarter bottom line beat estimates on a favorable current-year medical utilization in Retail segment relative, lower tax rate and a positive impact of share buybacks." (5/25/2018)
- 2. Cantor Fitzgerald analysts commented, "This morning, Humana announced it would acquire a 40% interest in Curo Health Services, a large, privately-held hospice company." (4/23/2018)
Who are some of Humana's key competitors?
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 56)
- Mr. Brian Andrew Kane, Sr. VP & CFO (Age 45)
- Mr. Timothy S. Huval, Chief HR Officer (Age 52)
- Ms. Jody L. Bilney, Chief Consumer Officer (Age 57)
- Mr. James Elmer Murray, Advisor (Age 64)
Has Humana been receiving favorable news coverage?
Media coverage about HUM stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Humana earned a news impact score of 0.09 on Accern's scale. They also assigned media headlines about the insurance provider an impact score of 45.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Humana's major shareholders?
Humana's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.85%), Newport Trust Co (1.37%), Wells Fargo & Company MN (1.25%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.14%) and Legal & General Group Plc (0.54%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Which institutional investors are selling Humana stock?
HUM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, OppenheimerFunds Inc., American Century Companies Inc., Royal Bank of Canada, FIL Ltd, Natixis, State of New Jersey Common Pension Fund D and Wells Fargo & Company MN. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Timothy S Huval and William Kevin Fleming. View Insider Buying and Selling for Humana.
Which institutional investors are buying Humana stock?
HUM stock was bought by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Ceredex Value Advisors LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., Summit Trail Advisors LLC, Mackay Shields LLC, Prudential Financial Inc. and ING Groep NV. View Insider Buying and Selling for Humana.
How do I buy shares of Humana?
Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Humana's stock price today?
One share of HUM stock can currently be purchased for approximately $294.72.
How big of a company is Humana?
Humana has a market capitalization of $40.19 billion and generates $53.77 billion in revenue each year. The insurance provider earns $2.45 billion in net income (profit) each year or $11.71 on an earnings per share basis. Humana employs 45,900 workers across the globe.
How can I contact Humana?
Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000.
MarketBeat Community Rating for Humana (HUM)
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Humana (NYSE:HUM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for Humana in the last 12 months. Their average twelve-month price target is $277.2941, suggesting that the stock has a possible downside of 6.00%. The high price target for HUM is $330.00 and the low price target for HUM is $221.00. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.72 | 2.74 | 2.52 |
| Ratings Breakdown: | 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $277.2941 | $274.8889 | $269.1667 | $251.80 |
| Price Target Upside: | 6.00% downside | 6.54% downside | 1.45% upside | 3.03% upside |
Humana (NYSE:HUM) Consensus Price Target History
Humana (NYSE:HUM) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Humana (NYSE:HUM) Dividend Information
Humana pays an annual dividend of $2.00 per share, with a dividend yield of 0.68%. HUM's next quarterly dividend payment will be made on Friday, July 27. The company has grown its dividend for the last 7 consecutive years and is increasing its dividend by an average of 10.60% each year. Humana pays out 17.08% of its earnings out as a dividend.
| Next Dividend: | 7/27/2018 |
| Annual Dividend: | $2.00 |
| Dividend Yield: | 0.68% |
| Dividend Growth: | 10.60% (3 Year Average) |
| Payout Ratio(s): | 17.08% (Trailing 12 Months of Earnings)
14.30% (Based on This Year's Estimates)
11.78% (Based on Next Year's Estimates)
12.91% (Based on Cash Flow)
|
| Track Record: | 7 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Humana (NYSE:HUM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/19/2018 | quarterly | $0.50 | 0.68% | 6/28/2018 | 6/29/2018 | 7/27/2018 |
| 2/6/2018 | Quarterly | $0.50 | 0.74% | 3/28/2018 | 3/30/2018 | 4/27/2018 |
| 11/2/2017 | quarterly | $0.40 | 0.62% | 12/28/2017 | 12/29/2017 | 1/26/2018 |
| 8/17/2017 | | $0.40 | | 9/28/2017 | 9/29/2017 | 10/16/2017 |
| 8/17/2017 | quarterly | $0.40 | 0.65% | 9/28/2017 | 8/29/2017 | 10/27/2017 |
| 4/20/2017 | quarterly | $0.40 | 0.75% | 6/28/2017 | 6/30/2017 | 7/31/2017 |
| 2/15/2017 | quarterly | $0.40 | 0.78% | 3/29/2017 | 3/31/2017 | 4/28/2017 |
| 10/26/2016 | quarterly | $0.29 | 0.67% | 1/10/2017 | 1/12/2017 | 1/27/2017 |
| 8/25/2016 | quarterly | $0.29 | 0.65% | 10/11/2016 | 10/13/2016 | 10/28/2016 |
| 4/21/2016 | quarterly | $0.29 | 0.66% | 6/28/2016 | 6/30/2016 | 7/29/2016 |
| 2/18/2016 | quarterly | $0.29 | 0.7% | 3/29/2016 | 3/31/2016 | 4/29/2016 |
| 10/29/2015 | quarterly | $0.29 | 0.65% | 12/28/2015 | 12/30/2015 | 1/29/2016 |
| 8/27/2015 | quarterly | $0.29 | 0.63% | 9/28/2015 | 9/30/2015 | 10/30/2015 |
| 4/17/2015 | quarterly | $0.29 | 0.65% | 6/26/2015 | 6/30/2015 | 7/31/2015 |
| 2/18/2015 | quarterly | $0.28 | 0.73% | 3/27/2015 | 3/31/2015 | 4/24/2015 |
| 10/31/2014 | quarterly | $0.28 | 0.81% | 12/29/2014 | 12/31/2014 | 1/30/2015 |
| 8/27/2014 | quarterly | $0.28 | 0.88% | 9/26/2014 | 9/30/2014 | 10/31/2014 |
| 4/30/2014 | quarterly | $0.28 | 1.02% | 6/26/2014 | 6/30/2014 | 7/25/2014 |
| 2/19/2014 | quarterly | $0.27 | 1.06% | 3/27/2014 | 3/31/2014 | 4/25/2014 |
| 10/30/2013 | quarterly | $0.27 | 1.17% | 12/27/2013 | 12/31/2013 | 1/31/2014 |
| 8/22/2013 | quarterly | $0.27 | 1.14% | 9/26/2013 | 9/30/2013 | 10/25/2013 |
| 4/25/2013 | quarterly | $0.27 | 1.47% | 6/26/2013 | 6/28/2013 | 7/26/2013 |
| 2/27/2013 | quarterly | $0.26 | 1.52% | 3/26/2013 | 3/28/2013 | 4/26/2013 |
(Data available from 1/1/2013 forward)
Humana (NYSE HUM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.60%
Institutional Ownership Percentage: 93.46%
Humana (NYSE HUM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/3/2018 | Bruce D Broussard | CEO | Sell | 17,604 | $286.17 | $5,037,736.68 | 89,259 |  |
| 5/3/2018 | Heidi S Margulis | Insider | Sell | 20,621 | $285.90 | $5,895,543.90 | 9,220 | |
| 3/9/2018 | Cynthia H Zipperle | SVP | Sell | 1,196 | $273.33 | $326,902.68 | 7,771 | |
| 2/27/2018 | M Todoroff Christopher | Insider | Sell | 16,389 | $273.37 | $4,480,260.93 | 13,447 | |
| 2/26/2018 | Bruce D Broussard | CEO | Sell | 14,075 | $274.32 | $3,861,054.00 | 113,896 | |
| 12/21/2017 | Brian P Leclaire | SVP | Sell | 1,679 | $245.97 | $412,983.63 | 9,888 | |
| 12/19/2017 | Timothy S Huval | VP | Sell | 1,382 | $246.04 | $340,027.28 | 11,557 | |
| 12/18/2017 | Jody L Bilney | SVP | Sell | 7,054 | $247.89 | $1,748,616.06 | 11,704 | |
| 9/1/2017 | Elizabeth D Bierbower | Insider | Sell | 9,786 | $259.00 | $2,534,574.00 | 18,042 | |
| 9/1/2017 | Timothy S Huval | VP | Sell | 7,803 | $258.14 | $2,014,266.42 | 8,831 | |
| 8/23/2017 | William Kevin Fleming | Insider | Sell | 3,071 | $250.98 | $770,759.58 | 7,681 | |
| 8/11/2017 | Bruce D Broussard | CEO | Sell | 12,000 | $251.88 | $3,022,560.00 | 80,086 | |
| 8/10/2017 | M Todoroff Christopher | VP | Sell | 22,935 | $252.52 | $5,791,546.20 | 24,001 | |
| 6/28/2017 | Brian P Leclaire | SVP | Sell | 4,971 | $240.00 | $1,193,040.00 | 14,258 | |
| 5/26/2017 | Heidi S Margulis | VP | Sell | 1,500 | $231.96 | $347,940.00 | 8,150 | |
| 5/5/2017 | Jody L Bilney | SVP | Sell | 4,600 | $230.16 | $1,058,736.00 | 8,978 | |
| 5/4/2017 | Bruce D Broussard | CEO | Sell | 118,231 | $225.82 | $26,698,924.42 | 171,170 | |
| 5/4/2017 | Timothy S Huval | VP | Sell | 13,939 | $225.86 | $3,148,262.54 | 23,639 | |
| 3/21/2017 | Jody L Bilney | SVP | Sell | 4,348 | $213.80 | $929,602.40 | 13,578 | |
| 3/6/2017 | James E Murray | COO | Sell | 31,151 | $213.62 | $6,654,476.62 | 45,635 | |
| 3/3/2017 | Cynthia H Zipperle | VP | Sell | 1,885 | $213.37 | $402,202.45 | 3,736 | |
| 2/24/2017 | Brian P Leclaire | SVP | Sell | 4,971 | $204.81 | $1,018,110.51 | 14,258 | |
| 2/22/2017 | Brian P Leclaire | SVP | Sell | 26,894 | $205.24 | $5,519,724.56 | 25,734 | |
| 2/22/2017 | James E Murray | COO | Sell | 9,523 | $204.69 | $1,949,262.87 | 76,798 | |
| 2/22/2017 | Roy A Beveridge | VP | Sell | 4,832 | $205.73 | $994,087.36 | 18,439 | |
| 2/21/2017 | Bruce D Broussard | CEO | Sell | 104,256 | $205.23 | $21,396,458.88 | 155,108 | |
| 2/21/2017 | Cynthia H Zipperle | CAO | Sell | 4,213 | $204.67 | $862,274.71 | 6,542 | |
| 2/21/2017 | David A. Jr/Ky Jones | Director | Sell | 27,000 | $205.04 | $5,536,080.00 | | |
| 2/21/2017 | James E Murray | COO | Sell | 70,332 | $205.20 | $14,432,126.40 | 76,798 | |
| 2/21/2017 | Jody L Bilney | SVP | Sell | 6,087 | $204.72 | $1,246,130.64 | 28,577 | |
| 2/21/2017 | M Todoroff Christopher | VP | Sell | 24,140 | $205.33 | $4,956,666.20 | | |
| 2/25/2016 | Brian P Leclaire | SVP | Sell | 183 | $176.11 | $32,228.13 | 17,301 | |
| 3/11/2015 | James E Murray | COO | Sell | 35,220 | $160.90 | $5,666,898.00 | | |
| 3/2/2015 | Brian P Leclaire | SVP | Sell | 5,500 | $161.79 | $889,845.00 | | |
| 2/25/2015 | Bruce D Broussard | CEO | Sell | 41,105 | $165.29 | $6,794,245.45 | | |
| 2/25/2015 | David A Jr/Ky Jones | Director | Sell | 6,100 | $165.39 | $1,008,879.00 | | |
| 2/24/2015 | Heidi S Margulis | VP | Sell | 3,665 | $164.44 | $602,672.60 | | |
| 8/22/2014 | Brian P Leclaire | SVP | Sell | 3,250 | $123.04 | $399,880.00 | | |
| 5/15/2014 | Heidi Margulis | VP | Sell | 3,345 | $119.56 | $399,928.20 | 8,730 | |
| 5/12/2014 | Marissa Peterson | Director | Sell | 2,026 | $123.30 | $249,805.80 | 1,358 | |
| 3/19/2014 | James Murray | COO | Sell | 36,833 | $116.59 | $4,294,359.47 | 89,892 | |
| 3/18/2014 | M Todoroff Christopher | VP | Sell | 8,000 | $113.20 | $905,600.00 | 18,225 | |
| 3/13/2014 | Bruce Broussard | CEO | Sell | 109,000 | $109.84 | $11,972,560.00 | 59,944 | |
| 3/10/2014 | Webster Roy Dunbar | Director | Sell | 9,587 | $110.30 | $1,057,446.10 | 1,458 | |
| 12/4/2013 | Marissa Peterson | Director | Sell | 1,147 | $103.54 | $118,760.38 | | |
| 12/2/2013 | M Todoroff Christopher | VP | Sell | 6,000 | $105.50 | $633,000.00 | 16,226 | |
| 11/26/2013 | Heidi Margulis | VP | Sell | 5,500 | $104.42 | $574,310.00 | 7,136 | |
| 11/8/2013 | David Jr/Ky Jones | Director | Sell | 11,000 | $95.00 | $1,045,000.00 | 143,339 | |
| 9/5/2013 | Elizabeth D Bierbower | Insider | Sell | 17,673 | $96.01 | $1,696,784.73 | | |
| 8/30/2013 | Heidi Margulis | VP | Sell | 3,319 | $93.35 | $309,828.65 | 10,801 | |
| 8/29/2013 | David Jr/Ky Jones | Director | Sell | 2,500 | $93.01 | $232,525.00 | 154,339 | |
| 8/23/2013 | Elizabeth Bierbower | Insider | Sell | 6,063 | $94.00 | $569,922.00 | 16,473 | |
| 8/15/2013 | Michael Mccallister | Director | Sell | 138,817 | $91.49 | $12,700,367.33 | 111,859 | |
| 8/13/2013 | Bruce Perkins | Insider | Sell | 9,000 | $93.47 | $841,230.00 | 10,985 | |
| 8/8/2013 | Steven Mcculley | VP | Sell | 10,000 | $92.54 | $925,400.00 | 9,327 | |
| 8/7/2013 | James Bloem | CFO | Sell | 33,000 | $91.79 | $3,029,070.00 | 21,767 | |
| 8/1/2013 | M Todoroff Christopher | VP | Sell | 39,596 | $90.30 | $3,575,518.80 | | |
| 6/24/2013 | Paul B K Kusserow | SVP | Sell | 34,219 | $84.60 | $2,894,927.40 | | |
| 6/18/2013 | Elizabeth D Bierbower | Insider | Sell | 8,033 | $83.29 | $669,068.57 | | |
| 5/30/2013 | James E Murray | COO | Sell | 11,000 | $81.96 | $901,560.00 | | |
| 5/9/2013 | Michael B Mccallister | Director | Sell | 281,312 | $77.72 | $21,863,568.64 | | |
(Data available from 1/1/2013 forward)
Humana (NYSE HUM) News Headlines
| Source: |
|
Humana (NYSE:HUM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Humana (NYSE:HUM) Income Statement, Balance Sheet and Cash Flow Statement
Humana (NYSE HUM) Stock Chart for Friday, May, 25, 2018
Loading chart…
